Cargando…
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
BACKGROUND: In older patients with overactive bladder (OAB), mirabegron, a β(3)-adrenoreceptor agonist, represents an alternative treatment that may have a favorable risk–benefit profile. OBJECTIVES: Our objective was to further examine the safety and tolerability of mirabegron versus placebo treatm...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473960/ https://www.ncbi.nlm.nih.gov/pubmed/32725584 http://dx.doi.org/10.1007/s40266-020-00783-w |